AviadoBio will combine its proprietary vMiX™ RNAi platform with Apertura’s novel human TfR1 capsid (TfR1 CapX™) to enable one ...
AviadoBio Ltd. ("AviadoBio") and Apertura Gene Therapy ("Apertura"), a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today announced a licensing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results